menu
    • menu

    Company profile for Meiji Seika Pharma

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Meiji Seika Pharma Co Ltd., the Meiji group's pharmaceutical division , is made up of more than 5700 workers dedicated to health and empowerment of people. Manufacturing and sale of ethical pharmaceuticals, agricultural chemicals and veterinary drugs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Meiji Seika Pharmajapan Flag
    Country
    Country
    Japan
    Address
    Address
    4-16, Kyobashi 2-chome, Chuo-ku, Tokyo 104-800
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.meiji.com/global/worldwide-locations.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 4926

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    Since 2022, there has been a significant surge in layoffs by pharmaceutical and biotech companies. While this trend continued into 2024, the industry showed signs of stabilization in the last four months of the year with the pace of layoffs slowing down. Nonetheless, 2024 was a challenging year. Data compiled by PharmaCompass indicates that over 25,000 layoffs were announced in 2024, driven by economic pressures, failed clinical trials, and strategic pivots. Bristol Myers Squibb and Johnson & Johnson led the layoffs with about 2,300 job cuts each. Bayer announced elimination of 1,800 positions.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available) US, Europe, China bear brunt of job cuts; Big Pharma hands pink slips to 10,000 Over 190 biopharma companies announced layoffs in 2024. The year began on a grim note — 27 firms announced significant job cuts in January 2024. By the yearend, Big Pharma alone had contributed more than 10,000 layoffs to the year’s total of over 25,000. Novartis announced over 1,200 job cuts in 2024. It eliminated 330 jobs after it acquired German biotech MorphoSys through the closure of sites in Munich and Boston. Similarly, Bayer announced significant reductions at its US and Swiss facilities.  North America saw increased retrenchments, especially at biotech hubs such as Boston, San Diego, and New Jersey. Massachusetts, with Boston and Cambridge as the epicenter of US biotechnology, saw around 4,000 layoffs, with companies like Relay Therapeutics, Editas Medicine, and Takeda driving the numbers. In San Diego, workforce reductions by Takeda, and Bavarian Nordic collectively resulted in over 900 job losses, significantly impacting the local biotech ecosystem. New Jersey was subject to broader restructuring efforts with BMS and Bayer contributing nearly 1,500 layoffs. The impact in Europe was equally severe. Germany, home to some of the world’s largest pharmaceutical companies, saw over 2,500 layoffs as Bayer and Boehringer Ingelheim scaled back operations. Novartis’ decision to shut down its Munich site added hundreds more to the tally. In Switzerland, Idorsia eliminated 270 positions. Dutch biotech UniQure reduced its workforce by 65 percent (around 300 jobs). That included the sale of a Massachusetts manufacturing facility to Genezen. Denmark also felt the strain, with Leo Pharma cutting 250 roles as part of a strategic revamp. China emerged as another focal point of workforce reductions in 2024. Global pharmaceutical giants, such as Merck and Johnson & Johnson, restructured their operations in response to market complexities in the region. Local companies such as Connect Biopharma, which is transitioning to a US-focused company, also scaled back their presence in the country.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Amylyx, FibroGen, Lyra, Athira drastically reduce staff over setbacks in clinical trials Clinical trial failures were one of the most significant drivers of layoffs in 2024. For instance, Amylyx Pharmaceuticals faced a devastating blow when its amyotrophic lateral sclerosis (ALS) therapy, Relyvrio, failed a confirmatory trial. This led to a 70 percent reduction in its workforce, leaving only 100 employees from the 384 full-time staff reported at the end of 2023. The company’s decision to pull the therapy from the market compounded the layoffs. BioMarin Pharmaceutical had to reduce its workforce, as it streamlined its pipeline in response to trial challenges. In August, the company announced a reduction of 225 employees, citing “organizational redesign efforts”. These layoffs followed 170 redundancies announced earlier in May. FibroGen, once considered a leader in oncology drug development, was among the most heavily impacted. The high-profile failure of its anti-CTGF antibody in two late-stage cancer trials led to the discontinuation of its lead candidate, resulting in a 75 percent reduction in its US workforce. Lyra Therapeutics also implemented a 75 percent workforce reduction, affecting 87 employees, after its chronic rhinosinusitis program struggled. Similarly, Athira Pharma cut 70 percent of its team after its Alzheimer’s candidate failed a phase 2/3 trial.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Cash crunch, mergers compel Kronos Bio, Editas, Vincerx, Gilead to downsize In addition to clinical failures, funding constraints played a pivotal role in reshaping the biotech landscape. Kronos Bio stood out as one of the hardest-hit firms, cutting 21 percent and 83 percent of its existing workforce in March and November, respectively, as it sought to divest assets and conserve cash. Editas Medicine’s inability to secure partnerships for its sickle cell program forced the company to revert to preclinical research, resulting in a 65 percent workforce reduction. The trend of scaling back R&D pipelines was particularly evident among biotechs struggling to advance preclinical programs to clinical trials. Boundless Bio and Senti Bio exemplified this, choosing to focus on a handful of promising candidates, while reducing discovery efforts. Consolidation often results in overlapping roles, leading to inevitable workforce reductions. Apart from the MorphoSys layoffs by Novartis, Vincerx Pharma faced job losses after it got acquired by Oqory (a clinical-stage ADC company). Vincerx had to cut its workforce by 55 percent.  Amid ongoing reorganization efforts, Gilead closed its Seattle, Washington (US), office and laid off 72 employees of its subsidiary Kite Pharma. Gilead also announced that its Kite facility in Philadelphia, Pennsylvania (US), would close by mid-2025. That was followed by 104 additional layoffs at its California headquarters. In April, it had cut 58 jobs in California. Gilead also announced that its Kite facility in Philadelphia would close by mid-2025. Vir Biotechnology reduced its workforce by 25 percent (i.e. 140 layoffs) to focus on its hepatitis program, and GlycoMimetics let go of 80 percent of its workforce after the FDA demanded an additional clinical trial for its leukemia treatment. Meanwhile, Lexicon Pharmaceuticals reduced its workforce by 60 percent after it stopped commercial operations and transitioned back to being a clinical stage company.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Our view It takes decades to build innovation ecosystems. The concentration of layoffs in major biotech hubs has raised concerns about the potential long-term impact on these ecosystems. In 2025, the key challenge will be to maintain the momentum of innovation, as organizations operate with a leaner workforce and a more focused pipeline.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4652

    https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch

    #PharmaFlow by PHARMACOMPASS
    16 Jan 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Meiji Seika Pharma Establishes Taiwan Meiji Pharma Subsidiary
    Meiji Seika Pharma Establishes Taiwan Meiji Pharma Subsidiary

    25 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241224059900/en

    BUSINESSWIRE
    25 Dec 2024
    Share Share
    Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
    Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

    14 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241113734839/en

    BUSINESSWIRE
    14 Nov 2024
    Share Share
    Japan Approves CSL And Arcturus' Updated COVID-19 Vaccine For JN.1 Strain
    Japan Approves CSL And Arcturus' Updated COVID-19 Vaccine For JN.1 Strain

    13 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240913667150/en

    BUSINESSWIRE
    13 Sep 2024
    Share Share
    Meiji Seika Pharma Opens Boston Office For Investment Opportunities
    Meiji Seika Pharma Opens Boston Office For Investment Opportunities

    08 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240808269845/en

    BUSINESSWIRE
    08 Aug 2024
    Share Share
    Meiji Seika to supply Japan with self-amplifying mRNA Covid-19 vaccine
    Meiji Seika to supply Japan with self-amplifying mRNA Covid-19 vaccine

    22 Mar 2024

    // ENDPTS

    https://endpts.com/meiji-seika-pharma-to-supply-japan-with-self-amplifying-mrna-covid-19-vaccine-in-fall-winter-of-2024/

    ENDPTS
    22 Mar 2024
    Share Share
    Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183
    Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183

    13 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231012881091/en

    BUSINESSWIRE
    13 Oct 2023
    Share Share

    JDMF

    read-more
    read-more

    01

    Ampicillin sodium

    JDMF

    PharmaVenue
    Not Confirmed
    arrow

    Ampicillin sodium

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Japan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Meiji Seika Pharma

    Registration Number : 217MF11156

    Registrant's Address : 2-4-16 Kyobashi, Chuo-ku, Tokyo

    Initial Date of Registration : 2005-12-12

    Latest Date of Registration : 2014-09-01

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Cefditoren Pivoxil

    JDMF

    PharmaVenue
    Not Confirmed
    arrow

    Cefditoren Pivoxil

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Japan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Meiji Seika Pharma

    Registration Number : 302MF10072

    Registrant's Address : 2-4-16 Kyobashi, Chuo-ku, Tokyo

    Initial Date of Registration : 2020-06-26

    Latest Date of Registration : 2020-06-26

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Day stations cyanocobalamin

    JDMF

    PharmaVenue
    Not Confirmed
    arrow

    04

    Doxorubicin Hydrochloride

    JDMF

    PharmaVenue
    Not Confirmed
    arrow

    05

    Doxorubicin hydrochloride

    JDMF

    PharmaVenue
    Not Confirmed
    arrow
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KDMF

    read-more
    read-more

    01

    Doxorubicin hydrochloride

    Japan
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Doxorubicin hydrochloride

    Japan
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Meiji Seika Pharma

    Registrant Name : Boxter Co., Ltd.

    Registration Date : 2021-02-17

    Registration Number : 20210217-210-J-674

    Manufacturer Name : Meiji Seika Pharma Co., Ltd. K...

    Manufacturer Address : 3-3, Kitakogyodanchi Kitakami-shi, Iwate-ken 024-0193, Japan

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    02

    Safeditorenpibosil

    Japan
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Safeditorenpibosil

    Japan
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Meiji Seika Pharma

    Registrant Name : Boryeong Co., Ltd.

    Registration Date : 2020-11-13

    Registration Number : 20201113-209-J-519

    Manufacturer Name : Meiji Seika Pharma Co., Ltd.

    Manufacturer Address : 2890, Kitagata, Kitagata-cho, Motosu-gun, Gifu-ken, Japan

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Meiji Seika Launches REZUROCK® Tablets in Japan for Chronic Graft-Versus-Host Disease

    Details:

    Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).


    Lead Product(s): Belumosudil

    Therapeutic Area: Immunology Brand Name: Rezurock

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Sanofi

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 22, 2024

    blank

    01

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Belumosudil

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Sanofi

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Meiji Seika Launches REZUROCK® Tablets in Japan for Chronic Graft-Versus-Host Disease

    Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

    Brand Name : Rezurock

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 22, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Meiji Seika Receives Approval for REZUROCK® in Japan for Chronic Graft-Versus-Host Disease

    Details:

    Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).


    Lead Product(s): Belumosudil

    Therapeutic Area: Immunology Brand Name: Rezurock

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Sanofi

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 26, 2024

    blank

    02

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Belumosudil

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Sanofi

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Meiji Seika Receives Approval for REZUROCK® in Japan for Chronic Graft-Versus-Host Disease

    Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

    Brand Name : Rezurock

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    March 26, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    New Drug Application for ME3208 Submitted in Japan for Chronic Graft-Versus-Host Disease

    Details:

    Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).


    Lead Product(s): Belumosudil

    Therapeutic Area: Immunology Brand Name: Rezurock

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Sanofi

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 27, 2023

    blank

    03

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Belumosudil

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Sanofi

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    New Drug Application for ME3208 Submitted in Japan for Chronic Graft-Versus-Host Disease

    Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

    Brand Name : Rezurock

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    June 27, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    ME3208 Receives Orphan Drug Designation in Japan for Chronic Graft-Versus-Host Disease

    Details:

    Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).


    Lead Product(s): Belumosudil

    Therapeutic Area: Immunology Brand Name: Rezurock

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Sanofi

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 24, 2023

    blank

    04

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Belumosudil

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Sanofi

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    ME3208 Receives Orphan Drug Designation in Japan for Chronic Graft-Versus-Host Disease

    Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

    Brand Name : Rezurock

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 24, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Novel Anti-PD-1 Agonist Antibody with Immunosuppressive Effect Discovered Through Joint Research Between Meiji Seika Pharma and The Foundation for Bio...

    Details:

    A novel anti-PD-1 agonist monoclonal antibody, which inhibits the function of PD-1 (anti-PD-1 blocking antibodies) leading in enhanced anti-tumor immunity.


    Lead Product(s): Monoclonal Antibody

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Large molecule

    Sponsor: Foundation for Biomedical Research and Innovation at Kobe

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 16, 2023

    blank

    05

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Monoclonal Antibody

    Therapeutic Area : Immunology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Foundation for Biomedical Research and Innovation at Kobe

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    A Novel Anti-PD-1 Agonist Antibody with Immunosuppressive Effect Discovered Through Joint Research...

    Details : A novel anti-PD-1 agonist monoclonal antibody, which inhibits the function of PD-1 (anti-PD-1 blocking antibodies) leading in enhanced anti-tumor immunity.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    January 16, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaque Psoriasis in the United States and Canada

    Details:

    In non-clinical studies, ME3183, a selective phosphodiesterase-4 (PDE4) inhibitor, showed greater anti-inflammatory effect and its inhibitory effect on TNF-α production was approximately 30-fold greater than the existing orally-available PDE4 inhibitor for psoriasis.


    Lead Product(s): ME3183

    Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: ME3183

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 07, 2022

    blank

    06

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ME3183

    Therapeutic Area : Trauma (Emergency, Injury, Surgery)

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaq...

    Details : In non-clinical studies, ME3183, a selective phosphodiesterase-4 (PDE4) inhibitor, showed greater anti-inflammatory effect and its inhibitory effect on TNF-α production was approximately 30-fold greater than the existing orally-available PDE4 inhibitor ...

    Brand Name : ME3183

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    April 07, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Meiji Completed Phase I Studies and Moves Onto Phase II Study of ME3183, a Selective PDE4 Inhibitor for the Treatment of Psoriasis

    Details:

    ME3183 is an orally-available and selective inhibitor for phosphodiesterase 4 (PDE4) discovered by Meiji. In the study, ME3183 has been shown to be safe and well-tolerated across the doses tested.


    Lead Product(s): ME3183

    Therapeutic Area: Dermatology Brand Name: ME3183

    Study Phase: Phase IProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 24, 2021

    blank

    07

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ME3183

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Meiji Completed Phase I Studies and Moves Onto Phase II Study of ME3183, a Selective PDE4 Inhibito...

    Details : ME3183 is an orally-available and selective inhibitor for phosphodiesterase 4 (PDE4) discovered by Meiji. In the study, ME3183 has been shown to be safe and well-tolerated across the doses tested.

    Brand Name : ME3183

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    August 24, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Intas Enters License Agreement with Meiji and Dong Commercialize DMB-3115

    Details:

    Under the terms of the agreement, Intas was granted the exclusive license rights to market DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia.


    Lead Product(s): Ustekinumab

    Therapeutic Area: Dermatology Brand Name: DMB-3115

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Intas Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement July 21, 2021

    blank

    08

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ustekinumab

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Intas Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Intas Enters License Agreement with Meiji and Dong Commercialize DMB-3115

    Details : Under the terms of the agreement, Intas was granted the exclusive license rights to market DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia.

    Brand Name : DMB-3115

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    July 21, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115

    Details:

    A single subcutaneous injection of DMB3115 in healthy volunteers was well tolerated. The reported adverse events corresponded with the known safety profile of ustekinumab.


    Lead Product(s): Ustekinumab

    Therapeutic Area: Dermatology Brand Name: DMB-3115

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Dong-A Socio Holdings

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 21, 2021

    blank

    09

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ustekinumab

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Dong-A Socio Holdings

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115

    Details : A single subcutaneous injection of DMB3115 in healthy volunteers was well tolerated. The reported adverse events corresponded with the known safety profile of ustekinumab.

    Brand Name : DMB-3115

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    May 21, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Eisai to Take Over Manufacturing and Marketing Approval for Equfina® 50 Mg Tablets (safinamide Mesilate)INn Japan from Meiji Seika Pharma

    Details:

    Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji. Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.


    Lead Product(s): Safinamide Mesylate

    Therapeutic Area: Neurology Brand Name: Equfina

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Eisai

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement September 07, 2020

    blank

    10

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed

    Meiji Seika Pharma

    Japan
    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Safinamide Mesylate

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Eisai

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Eisai to Take Over Manufacturing and Marketing Approval for Equfina® 50 Mg Tablets (safinamide Me...

    Details : Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji. Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.

    Brand Name : Equfina

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    September 07, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Meiji Seika Pharma and get a quotation

    Meiji Seika Pharma is a supplier offers 28 products (APIs, Excipients or Intermediates).

    Find a price of Doxorubicin Hydrochloride bulk with DMF, CEP, JDMF offered by Meiji Seika Pharma

    Find a price of Daunorubicin HCl bulk with DMF, CEP offered by Meiji Seika Pharma

    Find a price of Cefditoren Pivoxil bulk with JDMF offered by Meiji Seika Pharma

    Find a price of Vitamin B12 bulk with JDMF offered by Meiji Seika Pharma

    Find a price of Ampicillin Sodium bulk with JDMF offered by Meiji Seika Pharma

    Find a price of Doxorubicin Hydrochloride bulk with JDMF offered by Meiji Seika Pharma

    Find a price of Sodium Hyaluronate bulk with CEP offered by Meiji Seika Pharma

    Find a price of ME3183 bulk with DMF offered by Meiji Seika Pharma

    Find a price of Arbekacin bulk offered by Meiji Seika Pharma

    Find a price of Colistin Sulfate bulk offered by Meiji Seika Pharma

    Find a price of Gentamicin Sulfate bulk offered by Meiji Seika Pharma

    Find a price of Habekacin bulk offered by Meiji Seika Pharma

    Find a price of Kanamycin Sulfate bulk offered by Meiji Seika Pharma

    Find a price of Neothramycins bulk offered by Meiji Seika Pharma

    Find a price of Penicillin G Potassium bulk offered by Meiji Seika Pharma

    Find a price of Penicillin G Procaine bulk offered by Meiji Seika Pharma

    Find a price of Pirarubicin HCl bulk offered by Meiji Seika Pharma

    Find a price of Talaporfin bulk offered by Meiji Seika Pharma

    Find a price of Therarubicin Tn bulk offered by Meiji Seika Pharma

    Find a price of PERSONNEL, PROCEDURES, FACILITIES AND CONTROLS bulk offered by Meiji Seika Pharma

    Find a price of ODAWARA PLANT LOCATED IN KANAGAWA, JAPAN bulk offered by Meiji Seika Pharma

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN OSAKA CITY, JAPAN. bulk offered by Meiji Seika Pharma

    Find a price of ME1111 DRUG SUBSTANCE bulk offered by Meiji Seika Pharma

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN KAWASAKI, KANAGAWA, JAPAN. bulk offered by Meiji Seika Pharma

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GIFU PLANT, JAPAN. bulk offered by Meiji Seika Pharma

    Find a price of FACILITY AND PROCEDURES AT THE KITAKAMI PLANT. bulk offered by Meiji Seika Pharma

    Find a price of ASHIGARA PLANT (WHERE THP-ADRIAMYCIN IS MFGR & CONTROLLED) bulk offered by Meiji Seika Pharma

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ASHIGARA, JAPAN. bulk offered by Meiji Seika Pharma

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search